Sharon Bio-Medici

Aurobindo Pharma, one of the leading drugmakers in India, has informed that it has received final approval from the US Food and Drug Administration (US FDA) for its Cefazolin injection in the strengths of 500 mg and 1 gram per vial.

According to the company, the injection is a Sterile Cephalosporin product under the anti-infective segment and is a generic equivalent to Abraxis Pharmaceutical Products' reference listed drug Cefazolin.

Aurobindo has 74 abbreviated new drug applications (ANDA) approved by the U. S. FDA.

Stock market analysts have maintained ‘buy’ rating on Cipla stock with an intraday target of Rs 231.

According to them, interested traders can purchase the stock around Rs 228 with a strict stop loss of Rs 225. If the stock market remains on positive track, the stock pricing becomes more attractive, and reach above Rs 232.
 

The Japanese drug maker major Daiichi Sankyo is all set for acquisition of majority shares in Ranbaxy Laboratories. The company has received approval of Sebi and FIPB to push the deal.

The Japanese major can invest its $4.6 billion in the Ranbaxy laboratories. Earlier, the company has acquired over 15% stake of Ranbaxy. It had announced to buy 34.8 per cent shares at the face value of Rs 737 per share. It has shown interest to buy 20 per cent additional stakes in the company.